Disease-Free Survival
Figure 1 · Panel Disease-Free_Survival
Panel Disease-Free_Survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Andrea B Apolo, Karla V Ballman, Guru Sonpavde, Stephanie Berg, William Y Kim, Rahul Parikh, Min Yuen Teo, Randy F Sweis, Daniel M Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J Morris, Jonathan E Rosenberg
N Engl J Med 392(1) 45-55
BACKGROUND: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery is unknown. METHODS: In this phase 3 trial, we randomly assigned patients, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks for 1 year or to undergo observation. Randomization was stratified according to pathological stage, centrally tested programmed death ligand 1 (PD-L1) status, and previous neoadjuvant chemotherapy. The coprimary end points were disease-free survival and overall survival in the intention-to-treat population. We considered the trial to be successful if either disease-free survival or overall survival was significantly longer with pembrolizumab than with observation. RESULTS: A total of 702 patients underwent randomization; 354 were assigned to receive pembrolizumab, and 348 were assigned to observation. As of July 5, 2024, the median duration of follow-up for disease-free survival was 44.8 months. The median disease-free survival was 29.6 months (95% confidence interval [CI], 20.0 to 40.7) with pembrolizumab and 14.2 months (95% CI, 11.0 to 20.2) with observation (hazard ratio for disease progression or death, 0.73; 95% CI, 0.59 to 0.90; two-sided P = 0.003). Grade 3 or higher adverse events (regardless of attribution) occurred in 50.6% of the patients in the pembrolizumab group and in 31.6% of the patients in the observation group. CONCLUSIONS: Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the National Institutes of Health and others; Alliance A031501 AMBASSADOR ClinicalTrials.gov number, NCT03244384.).
3 个 Figure · 4 个 KM 面板
Figure 1:. Disease-Free Survival Kaplan-Meier plots for disease-free survival in the intention-to-treat population. HR=hazard ratio. Tick marks indicate patient censored at the last disease evaluation prior to analysis or treatment with alternative therapy prior to a disease-free survival event.
Figure 1 · Panel Disease-Free_Survival
Panel Disease-Free_Survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2:. Disease-Free Survival by PD-L1 Status Kaplan-Meier plots for disease-free survival based on A] PD-L1 negative tumors and B] PD-L1 positive tumors HR=hazard ratio. Tick marks indicate patient censored at the last disease evaluation prior to analysis or treatment with alternative therapy prior to a disease-free survival event.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4:. Overall Survival Kaplan-Meier plots for preliminary overall survival in the intention-to-treat population. HR=hazard ratio. Tick marks indicate data censored at the follow-up.
Figure 4 · Panel Figure_4
Panel Figure_4 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。